
Cgbrad 7.5mg Tablet
Marketer
Cmg Biotech Pvt Ltd
Salt Composition
Ivabradine (7.5mg)
Overview Cgbrad 7.5mg Tablet
Cardiogard 7.5mg tablets treat angina pectoris (chest pain stemming from heart problems) and long-term heart failure. It improves cardiac efficiency by reducing heart rate, thus easing chest pain and lowering the risk of hospital readmission for heart failure. Dosage is condition-specific. As treatment is typically lifelong, discontinuation requires physician consultation. Administer daily at the same time with food. Overdosage may cause bradycardia (slow heart rate), fatigue, and shortness of breath; seek immediate medical attention if this occurs. Common side effects include transient visual disturbances, bradycardia, hypertension, atrial fibrillation, vertigo, blurred vision, and electrocardiographic alterations. Serious adverse events like syncope (fainting) and significant heart rhythm changes necessitate urgent medical care. Refrain from driving until the drug's effects are known. Avoid Cardiogard 7.5mg if you have severe hepatic impairment, bradycardia, cardiac arrhythmias, very low blood pressure, or recently worsened heart failure. It interacts adversely with certain antihypertensives, antifungals, and antiretrovirals. Contraindicated during pregnancy, attempts at conception, and breastfeeding.
Primary Ingredients of Cgbrad 7.5mg Tablet
No information provided. Please provide the text you wish me to rephrase.
Uses of Cgbrad 7.5mg Tablet
Managing angina pectoris and heart failure.
Major Benefits of Cgbrad 7.5mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. The 7.5mg Cgbrad tablet should be swallowed whole; do not crush, chew, or break it. Administer this medication with food.
Common Side effects of Cgbrad 7.5mg Tablet:
- Slow heart rate
- Luminous phenomena (Enhanced brightness)
- High blood pressure
- Atrial fibrillation
- Dizziness
- Blurred vision
- ECG changes
How to use Cgbrad 7.5mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Cgbrad 7.5mg Tablet should be administered with a meal.
How Cgbrad 7.5mg Tablet works:
Cardiogard 7.5mg tablets decrease heart rate, thereby reducing the heart's oxygen demand and improving its overall efficiency.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Cgbrad 7.5mg Tablet lacks established safety data. Physician consultation is advised.
PregnancyUNSAFE
The use of Cgbrad 7.5mg tablets is strongly contraindicated during pregnancy. Pregnant individuals should consult their physician immediately, as research in both animals and pregnant women has revealed substantial adverse effects on fetal development.
Breast feedingUNSAFE
Lactation and the use of Cgbrad 7.5mg tablets are incompatible. Evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Driving ability may be impaired by Cgbrad 7.5mg Tablet, a medication that can induce transient visual disturbances, primarily phosphenes. Night driving, in particular, requires consideration of this potential side effect.
KidneyCAUTION
Patients with severe kidney impairment should exercise caution when using Cgbrad 7.5mg tablets, as dose modification may be necessary. Physician consultation is advised. Data regarding Cgbrad 7.5mg tablet use in such patients is limited.
LiverCAUTION
Patients with liver impairment should use Cgbrad 7.5mg tablets cautiously, potentially requiring dosage modification. Physician consultation is advised. Cgbrad 7.5mg tablets are contraindicated in patients exhibiting severe hepatic dysfunction.
What if you forget to take Cgbrad 7.5mg Tablet :
Omit any missed Cgbrad 7.5mg Tablet dose and resume your regular medication schedule. Avoid taking a double dose.
Facts to Know About Cgbrad 7.5mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Benzazepine-based compound |
| Developing Habits | No. |
| Treatment Category | Heart |
| Behavior Class | Sodium channel blockers targeting the sinoatrial node (I<sub>f</sub> current) |
